Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tango Therapeutics, Inc. (TNGX : NSDQ)

• Company Description    Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass. Number of Employees: 155

• Price / Volume Information    Yesterday's Closing Price: $5.70 Daily Weekly Monthly 20 Day Moving Average: 2,579,676 shares Shares Outstanding: 108.39 (millions) Market Capitalization: $617.85 (millions) Beta: 1.63 52 Week High: $12.02 52 Week Low: $1.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 27.52% 23.69% 12 Week 314.55% 259.35% Year To Date 84.47% 74.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 BROOKLINE AVE. SUITE 901 - BOSTON,MA 02215 USA ph: 857-320-4900 fax: - ir@tangotx.com http://www.tangotx.com

• General Corporate Information    Officers Barbara Weber - Chief Executive Officer; President and Director Alexis Borisy - Chairman Daniella Beckman - Chief Financial Officer Lesley Ann Calhoun - Director Kanishka Pothula - Director Peer Information Tango Therapeutics, Inc. (CORR.) Tango Therapeutics, Inc. (RSPI) Tango Therapeutics, Inc. (CGXP) Tango Therapeutics, Inc. (BGEN) Tango Therapeutics, Inc. (GTBP) Tango Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87583X109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 108.39 Most Recent Split Date: (:1) Beta: 1.63 Market Capitalization: $617.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.36 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.70 Price/Cash Flow: - Price / Sales: 15.07 EPS Growth vs. Year Ago Period: -2.86% vs. Previous Quarter: -2.86% Sales Growth vs. Year Ago Period: -16.67% vs. Previous Quarter: 30.97% ROE 06/30/25 - - 03/31/25 - -62.75 12/31/24 - -55.40 ROA 06/30/25 - - 03/31/25 - -39.94 12/31/24 - -35.78 Current Ratio 06/30/25 - - 03/31/25 - 6.26 12/31/24 - 6.98 Quick Ratio 06/30/25 - - 03/31/25 - 6.26 12/31/24 - 6.98 Operating Margin 06/30/25 - - 03/31/25 - -322.67 12/31/24 - -309.73 Net Margin 06/30/25 - - 03/31/25 - -322.67 12/31/24 - -309.73 Pre-Tax Margin 06/30/25 - - 03/31/25 - -322.17 12/31/24 - -309.24 Book Value 06/30/25 - - 03/31/25 - 1.54 12/31/24 - 1.86 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©